Tyme Technologies Inc banner
T

Tyme Technologies Inc
F:RFL

Watchlist Manager
Tyme Technologies Inc
F:RFL
Watchlist
Price: 0.3161 EUR 13.83% Market Closed
Market Cap: €54.4m

Multiples-Based Value

RFL price has not been updated for more than 4 months. This may indicate that the stock has been delisted.

There is not enough data to reliably calculate the multiples-based value of RFL.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RFL Multiples-Based Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

RFL Competitors Multiples
Tyme Technologies Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Tyme Technologies Inc
F:RFL
54.4m EUR 0 -2.7 0.5 0.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
373.2B USD 6.1 89.3 14.8 20.5
US
Exact Sciences Corp
NASDAQ:EXAS
355.4B USD 6.2 -96.2 951.3 -107.4
US
Amgen Inc
NASDAQ:AMGN
190.4B USD 5.1 24.5 14.2 14.2
US
Gilead Sciences Inc
NASDAQ:GILD
169.9B USD 5.7 19.8 12.4 15.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.2B USD 9.3 28.3 21.2 22.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80B USD 5.5 17.4 12.9 14.7
AU
CSL Ltd
ASX:CSL
69.6B AUD 3.2 34.9 11.5 14.4
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
P/S Multiple
Revenue Growth P/S to Growth
US
T
Tyme Technologies Inc
F:RFL
Average P/S: 3 369 302.5
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.1
9%
0.7
US
Exact Sciences Corp
NASDAQ:EXAS
6.2
12%
0.5
US
Amgen Inc
NASDAQ:AMGN
5.1
3%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
5.7
5%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.3
11%
0.8
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
10%
0.5
AU
CSL Ltd
ASX:CSL
3.2
4%
0.8
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
US
T
Tyme Technologies Inc
F:RFL
Average P/E: 35.7
Negative Multiple: -2.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
89.3
97%
0.9
US
Exact Sciences Corp
NASDAQ:EXAS
Negative Multiple: -96.2 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
24.5
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
19.8
16%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.3
17%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.4
13%
1.3
AU
CSL Ltd
ASX:CSL
34.9
10%
3.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
T
Tyme Technologies Inc
F:RFL
Average EV/EBITDA: 129.8
0.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.8
12%
1.2
US
Exact Sciences Corp
NASDAQ:EXAS
951.3
261%
3.6
US
Amgen Inc
NASDAQ:AMGN
14.2
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
9%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.2
16%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.9
18%
0.7
AU
CSL Ltd
ASX:CSL
11.5
7%
1.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
T
Tyme Technologies Inc
F:RFL
Average EV/EBIT: 14.6
0.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
20.5
23%
0.9
US
Exact Sciences Corp
NASDAQ:EXAS
Negative Multiple: -107.4 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
14.2
3%
4.7
US
Gilead Sciences Inc
NASDAQ:GILD
15.3
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.2
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.7
23%
0.6
AU
CSL Ltd
ASX:CSL
14.4
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett